Download PDF
Semin Thromb Hemost 2009; 35(8): 715-718
DOI: 10.1055/s-0029-1245103
EDITORIAL

© Thieme Medical Publishers

Farewell to 2009!

Emmanuel J. Favaloro1
  • 1Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW Australia
Further Information

Publication History

Publication Date:
18 February 2010 (online)

    Permissions and Reprints

The end of any year is a good time to reflect on the past. Welcome to the end of another year of Seminars in Thrombosis and Hemostasis, the first year with a reshaped and expanded editorial team, including a new editor in chief. We have mentioned several times in the past the long history that has led to this recent editorial restructuring, including the passing of the journal's founding editor in chief, Eberhard F. Mammen, in 2008.[1] [2] [3] [4] [5] [6] [7] [8]

I would very much like to thank our entire editorial team, our guest editors, and all the authors who have contributed articles for their respective contributions to this journal over the past year. I would also like to thank all the members of the Thieme team, whose contribution to the success or otherwise of this journal is critical but goes generally unrecognized. In particular, I would like to acknowledge the invaluable assistance of Xenia Golovchenko, the Production Editor for Thieme Medical Publishers, who is our first and main port of call for bringing every issue of Seminars in Thrombosis and Hemostasis to press.

It is also my great pleasure to announce another increase in this journal's Impact Factor (IF), which rose to 3.695 for 2008 (Fig. [1]). Although I maintain the IF can be misused, and there are other markers of journal quality to consider,[9] [10] this increase in IF does suggest that Seminars in Thrombosis and Hemostasis is on the right path. I have identified for those of you who may be interested the top-30 most highly cited articles from this journal using data from the past 3 years (i.e., 2006, 2007, and 2008) (Table [1]).[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40]

Figure 1 Seminars in Thrombosis and Hemostasis Impact Factor.

Table 1 The Top-30 Most Highly Cited Articles in Seminars in Thrombosis and Hemostasis Rank Article 1 Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32(suppl 1):49–60 2 Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32(1):11–23 3 Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32(1):54–70 4 Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006;32(1):24–32 5 Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006;32(suppl 1):61–68 6 Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32(5):456–471 7 Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32(1):33–39 8 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006;32(suppl 1):3–15 9 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33(4):313–320 10 Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006;32(4):307–340 11 Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006;32(suppl 1):77–85 12 Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32(suppl 1):32–38 13 Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost 2006;32(8):838–847 14 Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32(3):174–207 15 Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32(suppl 1):98–110 16 de Lamirande E. Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin Thromb Hemost 2007;33(1):60–68 17 Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32(5):537–545 18 Kavanagh D, Goodship TH. Membrane cofactor protein and factor I: mutations and transplantation. Semin Thromb Hemost 2006;32(2):155–159 19 Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. Semin Thromb Hemost 2007;33(2):128–135 20 Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 2005;31(6):691–699 21 Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006;32(1):5–10 22 Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005;31(6):681–690 23 Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007;33(5):557–568 24 Favaloro EJ, Bonar R, Kershaw G, et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006;32(5):505–513 25 Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Semin Thromb Hemost 2005;31(6):709–716 26 Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006;32(4):372–380 27 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–809 28 Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006;32(6):626–635 29 Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006;32(7):651–658 30 Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33(3):273–282

Finally, a short note to confirm that the same editorial team will be staying with Seminars in Thrombosis and Hemostasis next year. We will continue to develop plans for the future content of this issue, and we are confident that we will be able to continue to bring you, the reader, the high-quality journal that you have come to expect. Table [2] lists the currently confirmed topics for issues we plan to publish over the next 18 months. At the same time, we recognize the need to retain some flexibility in our plans and potentially to add additional material of current interest and controversy as the need arises.

Table 2 Current Planned Topics for Future Issues of Seminars in Thrombosis and Hemostasis • Endothelial cells: heterogeneous and underrecognized moderators of thrombosis and hemostasis • Microparticles in health and disease • Recombinants in thrombosis and hemostasis: clinical therapy and research tools • Hemolytic-uremic syndrome • Platelet-induced inflammation in cardiovascular diseases • Global hemostasis • Endocrine disorders and thrombosis and hemostasis • Quality in thrombosis and hemostasis • Pediatric issues in hemostasis and thrombosis • Disseminated intravascular coagulation • Cerebrovascular thrombosis and hemostasis • Laboratory and clinical identification and treatment of bleeding disorders

We look forward to another interesting year of reading in 2010!

REFERENCES

Emmanuel J FavaloroPh.D. M.A.I.M.S. 

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)

Westmead Hospital, WSAHS, Westmead, Australia

Email: emmanuel.favaloro@swahs.health.nsw.gov.au

      >